Sanofi-Aventis names Covance as primary R&D partner in $2.2 billion deal
This article was originally published in Scrip
Executive Summary
In an apparent attempt to avoid the R&D job attrition that has swept other big pharma companies recently, Sanofi-Aventis is to pay Covance $1.2-2.2 billion as part of a 10-year R&D outsourcing agreement that will see hundreds of R&D employees in France and the UK transfer to the US CRO.